Clients often ask us whether the MDL Panel will coordinate their cases and, if so, in what district and before which judge. We’ve tried in the past to “Mak[e] Book On The MDL Panel,” but we limited our investigation to product liability cases.
A research associate at the Federal Judicial Center and a
We’re running out of headlines for these posts: We’ve already used “Pre-Service Removals — For The Umpteenth Time” and “Pre-Service Removals: They Keep On Coming.”
What’s a blogger to do?
Even if we’ve run out of ideas for creative headlines, we can at least do the non-creative piece of this blogging
This is a Bexis only post. Herrmann represents Wyeth and doesn’t want to go on record on this.
We mentioned the Montgomery v. Wyeth case before, here. Well we’re pleased to report that the Sixth Circuit today affirmed the defense summary judgment in Montgomery, slip op. here. The moral of Montgomery is
Our stock in trade is words, but images can be more powerful.
Oddly enough, political cartoons that contain no words (and are not even funny) can be among the most powerful of all.
We loved the 1960s image (was it by Herblock?) of students protesting the Vietnam War outside the Lincoln Memorial in Washington,
We know, we know: Lawyers ain’t math majors.
But this requires only arithmetic, for heaven’s sake:
Three men were on a business trip and had to stay in a hotel over night. The price of the room was $30.00, so the men decided to split one room, three ways. Each one paid $10.00. Well after
We try not to wear out our welcome with our subscribers by publishing multiple posts in a single day, but there’s more breaking news that we feel compelled to report today. It’s in the Bausch & Lomb ReNu with MoistureLoc MDL. (Herrmann is writing this one up alone, since Bexis’s firm is involved in the
This just in:
(Actually, it came in late yesterday, but we were first busy and then tired. Sorry.)
In April 2008, the FDA recalled all lots of the drug Digitek (distributed by Mylan and UDL Laboratories), because the tablets may have contained too much of the drug’s active ingredient, exposing certain patients to risk.
First
We’ve been following with interest the recent activities in the Zyprexa litigation, since it looks like the plaintiffs in this batch of cases are dropping like flies. We admit, though, that we haven’t been particularly complete about those developments, since our prior posts describe only five summary judgment grants.
We’re not sure whether the Zyprexa
We may not have a sense of humor, but we can borrow Dana Summers’.
(H/T to Point of Law.)
As often happens when we blog about blogging, we became suddenly popular on Monday:
We’re purists? Who knew? (Maryland Injury Lawyer Blog)
Experiment with a dark blog for a month before announcing your blog publicly. (Legal Blog Watch)
My blogolater can beat up your blogolater. (Simple Justice)
A